Roche Signs 1.16B Obesity Drug Deal
Swiss drugmaker Roche has agreed to a licensing deal worth up to 1.16 billion dollars with Rona Therapeutics for an investigational obesity drug. The agreement includes an upfront payment of 100 million dollars and potential milestone payments.
Xurve View
Insights:
Xurve View
ROCHE HOLDING AG-BR agreed to a licensing deal worth up to $1.16B with Rona Therapeutics for an investigational obesity drug candidate, the China biotech firm said on Tuesday morning.
